Table 2

levels of liver parameters at baseline after Robusta oil treatment and during follow-up

Parameter

Normal limits

Baseline

Treatment

Follow-up1

Follow-up 2


n = 15

n = 15

n = 14

n = 14

Alanine aminotransferase

< 45 IU/l

0.38 [0.36,0.56]

0.67 [0.58,1.27]**

0.49 [0.39,0.72]*

0.39 [0.35,0.53]

Aspartate aminotransferase

< 50 IU/l

0.32 [0.26,0.38]

0.44 [0.26,0.56]

0.32 [0.28,0.42]

0.38 [0.28,0.41]

Alkaline phosphatase

40 – 125 U/l

0.45 [0.36,0.58]

0.43 [0.35,0.54]

0.42 [0.34,0.51]*

0.49 [0.37,0.53]

Amylase

35 – 130 U/l

0.50 [0.45,0.61]

0.48 [0.38,0.52]

0.49 [0.46,0.58]

0.47 [0.42,0.57]

Bilirubin

< 17 umol/l

0.47 [0.41,0.65]

0.53 [0.35,0.65]

0.65 [0.57,0.82]**

0.53 [0.40,0.74]

γ-glutamyltranspeptidase

< 40 U/l for women

< 75 U/l for men

0.29 [0.24,0.38]

0.25 [0.20,0.45]

0.31 [0.27,0.51]

0.34 [0.25,0.46]

Lactate dehydrogenase

230 – 485 IU/l

0.60 [0.56,0.61]

0.61 [0.49,0.65]

0.60 [0.50,0.64]

0.54 [0.52,0.65]


All values are medians in units of times the upper limit of normal with the 25th and 75th percentile between brackets. Treatment values were obtained after 16 days of Robusta oil treatment. Follow-up 1 took place four weeks after termination of the intervention and Follow-up2 eight weeks after termination. * value differs significantly from baseline (p < 0.05) in the Wilcoxon signed-rank test. ** p < 0.01

Boekschoten et al. Nutrition Journal 2004 3:7   doi:10.1186/1475-2891-3-7

Open Data